PTPN11 and cancer: The primary challenge with orthosteric inhibitors is to achieve sufficient selectivity for SHP2 over other cellular phosphatases, which may be further thwarted by the SHP2 cancer mutations that localize to residues near the active site, such as S502, G503, and Q510.